{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:18:13Z","timestamp":1791332293447,"version":"4.3.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comprehensive Psychiatry"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.comppsych.2024.152486","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T11:30:55Z","timestamp":1713180655000},"page":"152486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Off-label higher doses of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: Safety and tolerability"],"prefix":"10.1016","volume":"133","author":[{"given":"Daniel Minkin","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oded Ben","family":"Arush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior","family":"Carmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alzbeta Juven","family":"Wetzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Zohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.comppsych.2024.152486_bb0005","series-title":"The global Burden of Disease: 2004 Update","first-page":"146","author":"World Health Organization","year":"2008"},{"key":"10.1016\/j.comppsych.2024.152486_bb0010","series-title":"New Oxford Textbook of Psychiatry","first-page":"987","article-title":"Obsessive\u2013compulsive disorder","author":"Carmi","year":"2020"},{"issue":"12","key":"10.1016\/j.comppsych.2024.152486_bb0015","doi-asserted-by":"crossref","first-page":"e0261169","DOI":"10.1371\/journal.pone.0261169","article-title":"Long durations from symptom onset to diagnosis and from diagnosis to treatment in obsessive-compulsive disorder: A retrospective self-report study","volume":"16","author":"Ziegler","year":"2021","journal-title":"PLoS ONE"},{"key":"10.1016\/j.comppsych.2024.152486_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocrd.2022.100709","article-title":"Delay to diagnosis in OCD","volume":"32","author":"Hezel","year":"2022","journal-title":"Journal of Obsessive-Compulsive and Related Disorders"},{"issue":"7","key":"10.1016\/j.comppsych.2024.152486_bb0025","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1176\/appi.ps.202000296","article-title":"Defining and addressing gaps in Care for Obsessive-Compulsive Disorder in the United States","volume":"72","author":"Senter","year":"2021","journal-title":"PS"},{"key":"10.1016\/j.comppsych.2024.152486_bb0030","series-title":"Obsessive-compulsive disorder: Current science and clinical practice","author":"Zohar","year":"2012"},{"key":"10.1016\/j.comppsych.2024.152486_bb0035","series-title":"Guideline watch (march 2013): Practice guideline for the treatment of patients with obsessive-compulsive disorder","author":"Koran","year":"2013"},{"issue":"2","key":"10.1016\/j.comppsych.2024.152486_bb0040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/13651501.2012.667114","article-title":"Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care","volume":"16","author":"Bandelow","year":"2012","journal-title":"Int J Psychiatry Clin Pract"},{"key":"10.1016\/j.comppsych.2024.152486_bb0045","first-page":"787","article-title":"Anafranil (G34586) in obsessive compulsive neurosis","volume":"68","author":"Renynghe de Voxrie","year":"1968","journal-title":"Acta Neurol Belg"},{"issue":"6","key":"10.1016\/j.comppsych.2024.152486_bb0050","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0006-3223(87)90199-5","article-title":"Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology","volume":"22","author":"Zohar","year":"1987","journal-title":"Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.comppsych.2024.152486_bb0055","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0165-0327(87)90023-1","article-title":"Drug treatment of obsessive-compulsive disorder","volume":"13","author":"Zohar","year":"1987","journal-title":"J Affect Disord"},{"issue":"12","key":"10.1016\/j.comppsych.2024.152486_bb0060","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1001\/archpsyc.1989.01810120030006","article-title":"Treatment of obsessive-compulsive disorder with clomipramine and Desipramine in children and adolescents: a double-blind crossover comparison","volume":"46","author":"Leonard","year":"1989","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"10.1016\/j.comppsych.2024.152486_bb0065","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/archpsyc.1987.01800230026006","article-title":"Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and healthy controls","volume":"44","author":"Zohar","year":"1987","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152486_bb0070","article-title":"Clomipramine","author":"Wilson","year":"2022","journal-title":"StatPearls"},{"issue":"3","key":"10.1016\/j.comppsych.2024.152486_bb0075","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0193-953X(05)70186-6","article-title":"Pharmacotherapy for obsessive-compulsive disorder","volume":"23","author":"Hollander","year":"2000","journal-title":"Psychiatr Clin North Am"},{"issue":"2","key":"10.1016\/j.comppsych.2024.152486_bb0080","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0924-977X(93)90266-O","article-title":"A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD study group","volume":"3","author":"Montgomery","year":"1993","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/j.comppsych.2024.152486_bb0085","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4088\/JCP.v60n0206","article-title":"A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder","volume":"60","author":"Pigott","year":"1999","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"10.1016\/j.comppsych.2024.152486_bb0090","article-title":"Pharmacologic strategies for treatment-resistant OCD: a review of the evidence","volume":"36","author":"Fineberg","year":"2006","journal-title":"Psychiatr Ann"},{"issue":"9","key":"10.1016\/j.comppsych.2024.152486_bb0095","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1176\/ajp.153.9.1232b","article-title":"High doses of sertraline for treatment-resistant obsessive-compulsive disorder","volume":"153","author":"Byerly","year":"1996","journal-title":"Am J Psychiatry"},{"issue":"5","key":"10.1016\/j.comppsych.2024.152486_bb0100","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1600-0447.1998.tb10108.x","article-title":"Response to high doses of citalopram in treatment-resistant obsessive-compulsive disorder","volume":"98","author":"Bejerot","year":"1998","journal-title":"Acta Psychiatr Scand"},{"issue":"7","key":"10.1016\/j.comppsych.2024.152486_bb0105","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1017\/S1092852900021258","article-title":"Obsessive-compulsive disorder: an open-label pilot trial of escitalopram","volume":"12","author":"Galv\u00e3o-de Almeida","year":"2007","journal-title":"CNS Spectr"},{"issue":"01","key":"10.1016\/j.comppsych.2024.152486_bb0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.v67n0103","article-title":"High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial","volume":"67","author":"Ninan","year":"2006","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.comppsych.2024.152486_bb0115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/YIC.0b013e3282f0f0c5","article-title":"High-dose escitalopram for the treatment of obsessive\u2013compulsive disorder","volume":"23","author":"Rabinowitz","year":"2008","journal-title":"Int Clin Psychopharmacol"},{"issue":"12","key":"10.1016\/j.comppsych.2024.152486_bb0120","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1017\/S1092852900023956","article-title":"Adequacy of pharmacotherapy among Medicaid-enrolled patients newly diagnosed with obsessive-compulsive disorder","volume":"14","author":"Hankin","year":"2009","journal-title":"CNS Spectr"},{"issue":"6","key":"10.1016\/j.comppsych.2024.152486_bb0130","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-induced liver injury","volume":"70","author":"Andrade","year":"2019","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.comppsych.2024.152486_bb0135","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ajg.2014.131","article-title":"ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury","volume":"109","author":"Chalasani","year":"2014","journal-title":"American Journal of Gastroenterology"},{"issue":"3","key":"10.1016\/j.comppsych.2024.152486_bb0140","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/JCP.0b013e3181a5233f","article-title":"Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis","volume":"29","author":"Serretti","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.comppsych.2024.152486_bb0145","series-title":"ZOLOFT (sertraline hydrochloride) [package insert]","author":"Pfizer Inc","year":"2024"},{"key":"10.1016\/j.comppsych.2024.152486_bb0150","unstructured":"s35s44s45lbl.pdf. Revised December 2016. Accessed November 2, 2023."},{"key":"10.1016\/j.comppsych.2024.152486_bb0155","series-title":"PROZAC (fluoxetine) [package insert]","author":"Eli Lilly and Company","year":"2017"},{"key":"10.1016\/j.comppsych.2024.152486_bb0160","series-title":"Lexapro (escitalopram oxalate) [package insert]","author":"H. Lundbeck A\/S","year":"2023"},{"key":"10.1016\/j.comppsych.2024.152486_bb0165","series-title":"Luvox (Fluvoxamine Maleate) [package insert]","author":"Jazz Pharmaceuticals, Inc","year":"2008"},{"issue":"10","key":"10.1016\/j.comppsych.2024.152486_bb0170","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4088\/JCP.09r05346blu","article-title":"Antidepressants and body weight: a comprehensive review and meta-analysis","volume":"71","author":"Serretti","year":"2010","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.comppsych.2024.152486_bb0175","doi-asserted-by":"crossref","first-page":"pyv126","DOI":"10.1093\/ijnp\/pyv126","article-title":"Drug-induced liver injury during antidepressant treatment: results of AMSP, a drug surveillance program","volume":"19","author":"Friedrich","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"10.1016\/j.comppsych.2024.152486_bb0180","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41386-021-01179-z","article-title":"Selective serotonin reuptake inhibitors and suicidal behaviour: a population-based cohort study","volume":"47","author":"Lagerberg","year":"2022","journal-title":"Neuropsychopharmacol"},{"issue":"6","key":"10.1016\/j.comppsych.2024.152486_bb0185","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/WNF.0000000000000108","article-title":"Antidepressant-induced sleep bruxism: prevalence, incidence, and related factors","volume":"38","author":"Uca","year":"2015","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"10.1016\/j.comppsych.2024.152486_bb0190","first-page":"91","article-title":"Effects of psychotropic drugs on seizure threshold: drug safety","volume":"25","author":"Pisani","year":"2002"},{"issue":"1","key":"10.1016\/j.comppsych.2024.152486_bb0195","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/JCP.0b013e318191c6a8","article-title":"Psychotropic drugs associated with corrected QT interval prolongation","volume":"29","author":"van Noord","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.comppsych.2024.152486_bb0200","series-title":"StatPearls [Internet]","article-title":"Serotonin syndrome","author":"Simon","year":"2023"},{"issue":"10","key":"10.1016\/j.comppsych.2024.152486_bb0205","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1177\/0269881109104850","article-title":"High-dose selective serotonin reuptake inhibitors in OCD: a systematic retrospective case notes survey","volume":"24","author":"Pampaloni","year":"2010","journal-title":"J Psychopharmacol"},{"issue":"4","key":"10.1016\/j.comppsych.2024.152486_bb0210","first-page":"533","article-title":"Serotonin syndrome","volume":"13","author":"Volpi-Abadie","year":"2013","journal-title":"Ochsner J"},{"issue":"10","key":"10.1016\/j.comppsych.2024.152486_bb0215","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.3390\/jcm8101640","article-title":"Management strategies for antidepressant-related sexual dysfunction: a clinical approach","volume":"8","author":"Montejo","year":"2019","journal-title":"JCM"},{"issue":"4","key":"10.1016\/j.comppsych.2024.152486_bb0220","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1017\/neu.2023.6","article-title":"Apathy associated with antidepressant drugs: a systematic review","volume":"35","author":"Masdrakis","year":"2023","journal-title":"Acta Neuropsychiatr"},{"issue":"3","key":"10.1016\/j.comppsych.2024.152486_bb0225","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/da.10126","article-title":"Obsessive-compulsive spectrum conditions in obsessive-compulsive disorder and other anxiety disorders","volume":"18","author":"Richter","year":"2003","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.comppsych.2024.152486_bb0230","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12888-014-0317-5","article-title":"Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis","volume":"14","author":"Veale","year":"2014","journal-title":"BMC Psychiatry"}],"container-title":["Comprehensive Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010440X24000373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010440X24000373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T09:04:51Z","timestamp":1729501491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010440X24000373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":45,"alternative-id":["S0010440X24000373"],"URL":"https:\/\/doi.org\/10.1016\/j.comppsych.2024.152486","relation":{},"ISSN":["0010-440X"],"issn-type":[{"value":"0010-440X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Off-label higher doses of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: Safety and tolerability","name":"articletitle","label":"Article Title"},{"value":"Comprehensive Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.comppsych.2024.152486","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152486"}}